Hanmi Pharm Balance Sheet Health
Financial Health criteria checks 6/6
Hanmi Pharm has a total shareholder equity of ₩1,100.2B and total debt of ₩563.5B, which brings its debt-to-equity ratio to 51.2%. Its total assets and total liabilities are ₩1,898.7B and ₩798.5B respectively. Hanmi Pharm's EBIT is ₩224.9B making its interest coverage ratio 9.4. It has cash and short-term investments of ₩255.2B.
Key information
51.2%
Debt to equity ratio
₩563.48b
Debt
Interest coverage ratio | 9.4x |
Cash | ₩255.18b |
Equity | ₩1.10t |
Total liabilities | ₩798.46b |
Total assets | ₩1.90t |
Recent financial health updates
Recent updates
Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Financial Position Analysis
Short Term Liabilities: A128940's short term assets (₩730.6B) exceed its short term liabilities (₩704.8B).
Long Term Liabilities: A128940's short term assets (₩730.6B) exceed its long term liabilities (₩93.7B).
Debt to Equity History and Analysis
Debt Level: A128940's net debt to equity ratio (28%) is considered satisfactory.
Reducing Debt: A128940's debt to equity ratio has reduced from 79.8% to 51.2% over the past 5 years.
Debt Coverage: A128940's debt is well covered by operating cash flow (38.4%).
Interest Coverage: A128940's interest payments on its debt are well covered by EBIT (9.4x coverage).